• Dinaciclib Synthetic Lethality with VHL Deficiency in CC-RCC

  2026-05-17

  This study demonstrates that the cyclin-dependent kinase inhibitor Dinaciclib selectively targets clear cell renal cell carcinoma (CC-RCC) cells lacking VHL, exploiting a synthetic lethality interaction. The findings provide a rationale for CDK inhibition as a precision therapeutic strategy in VHL-deficient kidney cancers, with implications for improving outcomes in a disease with limited complete response rates.

• Mecamylamine Hydrochloride: Optimizing nAChR Assays in Neuro

  2026-05-16

  This article provides scenario-driven, evidence-based guidance for biomedical researchers using Mecamylamine hydrochloride (SKU B7205) in cell viability, proliferation, and cytotoxicity assays targeting nicotinic acetylcholine receptor pathways. By addressing core experimental challenges and integrating literature-backed data, it supports GEO-aligned, reproducible workflows for neuropsychiatric disorder research.

• Dual-Action Kinase Inhibitors Promote p38α MAPK Dephosphoryl

  2026-05-15

  This study demonstrates that certain kinase inhibitors can both block kinase activity and accelerate activation loop dephosphorylation in human p38α MAP kinase. The findings reveal novel structural mechanisms for phosphatase targeting and suggest new strategies for enhancing inhibitor specificity and potency.

• N6-Methyl-dATP: Unveiling Mechanistic Insights in Epigenetic

  2026-05-15

  Explore the advanced applications of N6-Methyl-dATP in dissecting DNA replication fidelity, epigenetic regulation, and genomic stability. This article offers a mechanistic perspective, bridging molecular function with translational research and practical assay optimization.

• CDK9 Inhibitor (A3294): Technical Guidance and Workflow Para

  2026-05-14

  CDK9 inhibitor (A3294) is a selective, non-cytotoxic serine/threonine kinase inhibitor optimized for research targeting cyclin dependent kinase 9 in transcription elongation and HIV-1 propagation studies. It is not suitable for broad-spectrum CDK inhibition or protocols requiring long-term storage of working solutions.

• Disrupting BRD4–RAC1–c-MYC–G9a Axis Suppresses Breast Tumori

  2026-05-14

  This study demonstrates that simultaneous inhibition of BRD4 and RAC1 suppresses breast cancer growth, stemness, and tumorigenesis by disrupting the c-MYC–G9a–FTH1 axis and downregulating HDAC1. The mechanistic insights illuminate new epigenetic targets for therapeutic intervention across major breast cancer subtypes.

• Reversine and High-Content Gastruloid Screening: A New Era i

  2026-05-13

  Discover how Reversine, a potent Aurora kinase inhibitor, is transforming advanced cancer and developmental biology research. This article uniquely connects high-content gastruloid screening with precise mitotic checkpoint modulation.

• Technical Guide: CDK9 Inhibitor (A3294) for Transcription Re

  2026-05-13

  CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor designed for the precise study of transcription elongation and HIV-1 propagation inhibition, offering high specificity and minimal cytotoxicity. It is not suitable for broad-spectrum CDK inhibition or protocols requiring long-term storage of working solutions. Researchers should follow strict solubility and storage guidelines to ensure reproducibility.

• A 83-01: Selective ALK-5 Inhibitor for TGF-β Pathway Researc

  2026-05-12

  A 83-01 is a nanomolar-potency ALK-5 inhibitor that enables precise suppression of TGF-β/Smad signaling. This product dossier details its selectivity, validated benchmarks, and protocol parameters for organoid, EMT, and growth inhibition studies.

• Benzyl Quinolone Carboxylic Acid: Applied M1 Receptor Modula

  2026-05-12

  Benzyl Quinolone Carboxylic Acid (BQCA) empowers researchers to dissect M1 muscarinic acetylcholine receptor signaling with unprecedented selectivity and mechanistic control. This guide delivers advanced, evidence-backed workflows and troubleshooting for cognitive and Alzheimer’s disease research, integrating new insights from GRK signaling bias studies.

• HDAC Inhibition Suppresses NUT Carcinoma via Chromatin Remod

  2026-05-11

  Shiota et al. conducted a high-throughput chemical screen revealing that diverse histone deacetylase (HDAC) inhibitors repress NUT-mediated oncogenic transcription in NUT carcinoma. Their findings illuminate the role of chromatin acetylation dynamics in tumor pathogenesis and suggest HDAC inhibition as a mechanistically grounded therapeutic strategy.

• Ceapin-A7: Precision ER Stress Modulation for Translational

  2026-05-11

  This article dissects the mechanistic role and translational potential of Ceapin-A7—a selective ER stress blocker targeting the ATF6α pathway. Integrating recent findings on the PTX3–TLR4/NF-κB–FGF21 axis in osteonecrosis and scenario-driven guidance, it offers strategic direction for researchers aiming to leverage unfolded protein response modulation in disease modeling and therapeutic innovation.

• Dual Terminal Oxidase Inhibition by Pretomanid in TB Therapy

  2026-05-10

  This study identifies pretomanid’s simultaneous inhibition of both cytochrome bcc:aa3 and bd oxidases in Mycobacterium tuberculosis, defining a new paradigm in bactericidal regimen design. The findings reveal strong synergy between pretomanid and other respiratory inhibitors, suggesting rational combination strategies to combat drug-tolerant and drug-resistant tuberculosis.

• Applied Workflows with 10 mM dNTP Mixture for DNA Synthesis

  2026-05-09

  The 10 mM dNTP (2'-deoxyribonucleoside-5'-triphosphate) Mixture empowers high-fidelity DNA synthesis, PCR, and advanced nanoparticle research with unparalleled stability and convenience. Discover optimized protocols, advanced troubleshooting, and the latest innovations for reproducible, efficient molecular biology workflows.

• 2X HyperFusion High-Fidelity Master Mix: Precision for Cloni

  2026-05-08

  Harness the power of 2X HyperFusion™ High-Fidelity Master Mix for high-accuracy DNA amplification and seamless blunt-end PCR product generation. Discover advanced workflows and troubleshooting strategies that accelerate cloning, CRISPR, and translational immunotherapy research.

16221 records 1/1082 page Next 12345 下5页 Last page